CRVO Stock Summary and Trading Ideas (Cervomed | NASDAQ:CRVO)

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Cervomed trades on the NASDAQ stock market under the symbol CRVO.

As of April 6, 2026, CRVO stock price declined to $3.98 with 30,585 million shares trading.

CRVO has a beta of -1.51, meaning it tends to be less sensitive to market movements. CRVO has a correlation of 0.10 to the broad based SPY ETF.

CRVO has a market cap of $36.83 million. This is considered a Sub-Micro Cap stock.

Last quarter Cervomed reported $9 million in Revenue and -$.88 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.19.

The top ETF exchange traded funds that CRVO belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

CRVO has underperformed the market in the last year with a price return of -70.7% while the SPY ETF gained +18.0%. CRVO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.9% and -5.9%, respectively, while the SPY returned -3.3% and +0.4%, respectively.

CRVO support price is $3.83 and resistance is $4.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRVO shares will trade within this expected range on the day.